460 related articles for article (PubMed ID: 30654246)
1. Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD).
Vukusic S; Brassat D; de Seze J; Izquierdo G; Lysandropoulos A; Moll W; Vanopdenbosch L; Arque MJ; Kertous M; Rufi P; Oreja-Guevara C
Mult Scler Relat Disord; 2019 Apr; 29():7-14. PubMed ID: 30654246
[TBL] [Abstract][Full Text] [Related]
2. Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis.
Šega-Jazbec S; Barun B; Horvat Ledinek A; Fabekovac V; Krbot Skorić M; Habek M
Mult Scler Relat Disord; 2017 Oct; 17():151-153. PubMed ID: 29055450
[TBL] [Abstract][Full Text] [Related]
3. Prevention and Management of Infusion-Associated Reactions in the Comparison of Alemtuzumab and Rebif(®) Efficacy in Multiple Sclerosis (CARE-MS) Program.
Caon C; Namey M; Meyer C; Mayer L; Oyuela P; Margolin DH; Rizzo M
Int J MS Care; 2015; 17(4):191-8. PubMed ID: 26300705
[TBL] [Abstract][Full Text] [Related]
4. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
Cohen JA; Coles AJ; Arnold DL; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Fisher E; Brinar VV; Giovannoni G; Stojanovic M; Ertik BI; Lake SL; Margolin DH; Panzara MA; Compston DA;
Lancet; 2012 Nov; 380(9856):1819-28. PubMed ID: 23122652
[TBL] [Abstract][Full Text] [Related]
5. Serum sickness (Like Reaction) in a patient treated with alemtuzumab for multiple sclerosis: A case report.
Lapucci C; Gualandi F; Mikulska M; Palmeri S; Mancardi G; Uccelli A; Laroni A
Mult Scler Relat Disord; 2018 Nov; 26():52-54. PubMed ID: 30223229
[TBL] [Abstract][Full Text] [Related]
6. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
Coles AJ; Twyman CL; Arnold DL; Cohen JA; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Miller T; Fisher E; Sandbrink R; Lake SL; Margolin DH; Oyuela P; Panzara MA; Compston DA;
Lancet; 2012 Nov; 380(9856):1829-39. PubMed ID: 23122650
[TBL] [Abstract][Full Text] [Related]
7. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.
Mayer L; Kappos L; Racke MK; Rammohan K; Traboulsee A; Hauser SL; Julian L; Köndgen H; Li C; Napieralski J; Zheng H; Wolinsky JS
Mult Scler Relat Disord; 2019 May; 30():236-243. PubMed ID: 30844611
[TBL] [Abstract][Full Text] [Related]
8. Acute leukocytosis during alemtuzumab treatment in patients with active relapsing-remitting multiple sclerosis.
Iovino A; Aruta F; Carotenuto A; Manganelli F; Iodice R
Mult Scler Relat Disord; 2019 Feb; 28():98-100. PubMed ID: 30580038
[TBL] [Abstract][Full Text] [Related]
9. Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis.
Zhang J; Shi S; Zhang Y; Luo J; Xiao Y; Meng L; Yang X
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD010968. PubMed ID: 29178444
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study.
Ziemssen T; Bass AD; Berkovich R; Comi G; Eichau S; Hobart J; Hunter SF; LaGanke C; Limmroth V; Pelletier D; Pozzilli C; Schippling S; Sousa L; Traboulsee A; Uitdehaag BMJ; Van Wijmeersch B; Choudhry Z; Daizadeh N; Singer BA;
CNS Drugs; 2020 Sep; 34(9):973-988. PubMed ID: 32710396
[TBL] [Abstract][Full Text] [Related]
11. Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis.
Hartung HP; Aktas O; Boyko AN
Mult Scler; 2015 Jan; 21(1):22-34. PubMed ID: 25344374
[TBL] [Abstract][Full Text] [Related]
12. Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.
Hersh CM; Cohen JA
Immunotherapy; 2014; 6(3):249-59. PubMed ID: 24762071
[TBL] [Abstract][Full Text] [Related]
13. Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management.
Cuker A; Bass AD; Nadj C; Agius MA; Steingo B; Selmaj KW; Thoits T; Guerreiro A; Van Wijmeersch B; Ziemssen T; Meuth SG; LaGanke CC; Thangavelu K; Rodriguez CE; Baker DP; Margolin DH; Jannsens A
Mult Scler; 2020 Jan; 26(1):48-56. PubMed ID: 30785358
[TBL] [Abstract][Full Text] [Related]
14. Reduction in ocrelizumab-induced infusion reactions by a modified premedication protocol.
Conte WL; Arndt N; Cipriani VP; Dellaria A; Javed A
Mult Scler Relat Disord; 2019 Jan; 27():397-399. PubMed ID: 30508784
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis.
Perumal JS; Foo F; Cook P; Khan O
Mult Scler; 2012 Aug; 18(8):1197-9. PubMed ID: 22252465
[TBL] [Abstract][Full Text] [Related]
16. Rituximab for relapsing-remitting multiple sclerosis.
He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
[TBL] [Abstract][Full Text] [Related]
17. A national, multi-center study in Germany to assess implementation of infusion management, treatment satisfaction and quality of life in MS patients receiving alemtuzumab.
Räuber S; Pawlitzki M; Korsen M; Kullmann JS; Thoene D; Pfeuffer S; Rolfes L; Nelke C; Melzer N; Ruck T; Meuth SG;
Mult Scler Relat Disord; 2022 Mar; 59():103670. PubMed ID: 35150978
[TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223.
Steingo B; Al Malik Y; Bass AD; Berkovich R; Carraro M; Fernández Ó; Ionete C; Massacesi L; Meuth SG; Mitsikostas DD; Pardo G; Simm RF; Traboulsee A; Choudhry Z; Daizadeh N; Compston DAS;
J Neurol; 2020 Nov; 267(11):3343-3353. PubMed ID: 32583052
[TBL] [Abstract][Full Text] [Related]
19. Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years.
Oh J; Achiron A; Celius EG; Chambers C; Derwenskus J; Devonshire V; Hellwig K; Hutton GJ; McCombe P; Moore M; Rog D; Schneider JR; Simm RF; Sousa L; Vincent SG; Chung L; Daizadeh N; Mitchell C; Compston DAS;
Mult Scler Relat Disord; 2020 Aug; 43():102146. PubMed ID: 32498033
[TBL] [Abstract][Full Text] [Related]
20. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
Coles AJ; Fox E; Vladic A; Gazda SK; Brinar V; Selmaj KW; Bass AD; Wynn DR; Margolin DH; Lake SL; Moran S; Palmer J; Smith MS; Compston DA
Lancet Neurol; 2011 Apr; 10(4):338-48. PubMed ID: 21397567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
